PicnicHealth, a San Francisco, CA-based patient-centered health technology company, closed a $60m Series C financing.
The round, which brought the total amount raised to date to more than $100m, was led by new investor B Capital Group with participation from existing investors Felicis Ventures and Amplify Partners. In conjunction with the funding, Adam Seabrook, Partner at B Capital Group, joined the PicnicHealth board of directors.
The company intends to use the funds to grow its portfolio of patient-centered real-world data cohorts across 30 new indications in complex, chronic, or rare conditions, introduce new capabilities to bring this depth and completeness to aid clinical trial sponsors in linking trial data with longitudinal real-world outcomes, and to streamline and speed the patient experience of gaining access to up-to-date medical records.
Founded in 2014 by Noga Leviner and Troy Astorino, PicnicHealth is a healthcare technology company that partners directly with patients to build deep real-world datasets. The company leverages machine learning, combined with human curation, to port complete medical records into an online application. The platform gives patients access to and control over their medical records and, with their consent, the opportunity to contribute this valuable data to further scientific research. The company partners with dozens of the world’s largest biopharma companies and academic research institutions.
The PicnicHealth Research Platform, since its launch in 2020, has powered the creation of patient-centered real-world data cohorts in hematology (including hemophilia, sickle cell disease, paroxysmal nocturnal hemoglobinuria, and immune thrombocytopenia); neurology (including multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, myasthenia gravis, and Huntington’s disease); and rare diseases (including lupus nephritis, primary biliary cholangitis, and Pompe disease). Dozens of leading global life sciences and biopharmaceutical companies use these datasets to surface the real-world experiences of more diverse populations than can be studied in clinical trials alone.
FinSMEs
27/06/2022